Ozempic Gastroparesis in Georgia: Which Patients Should Be Monitored?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Targeted Legal Guidance

If you or a loved one is taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may be wondering about the risk of gastroparesis. This page explains who may need closer monitoring for this condition in Georgia, building on a long tradition of patient education and evidence-based guidance. Here we outline the key signs, risk factors, and steps to take.

Understanding Ozempic and Its Link to Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes mellitus. Its pharmacological action includes slowing gastric emptying, which can lead to gastrointestinal adverse effects. Among the most serious potential complications is gastroparesis, a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, abdominal pain, and early satiety. Clinical presentation and diagnosis of gastroparesis typically involve a history of persistent nausea, vomiting, postprandial fullness, and abdominal discomfort. Diagnosis is confirmed through gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. In patients taking Ozempic, these symptoms may be exacerbated or newly induced due to the drug's effect on gastric motility. The pharmacology of Ozempic involves activation of GLP-1 receptors, which slows gastric emptying and reduces postprandial glucose excursions. However, this mechanism can also result in significant gastrointestinal adverse reactions. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients include nausea (placebo 6.1%, Ozempic 0.5 mg 15.8%, Ozempic 1 mg 20.3%), vomiting (placebo 2.3%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 9.2%), diarrhea (placebo 1.9%, Ozempic 0.5 mg 8.5%, Ozempic 1 mg 8.8%), abdominal pain (placebo 4.6%, Ozempic 0.5 mg 7.3%, Ozempic 1 mg 5.7%), and constipation (placebo 1.5%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 3.1%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Mechanistic Pathways and Clinical Evidence

Mechanistic pathways linking Ozempic to gastroparesis involve the drug's effect on gastric motility. GLP-1 receptor agonists delay gastric emptying, which can lead to retained gastric contents. This is supported by postmarketing reports of pulmonary aspiration in patients undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking Ozempic, including whether modifying preoperative fasting recommendations or temporarily discontinuing the drug could reduce the incidence of retained gastric contents (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). Observational evidence suggests that extended GLP-1 RA withholding, 24-hour clear liquid diets, and pre-procedural gastric point-of-care ultrasound may be associated with reduced retained gastric contents in selected patient populations, but the evidence base remains limited, and a modest aspiration risk cannot be excluded (https://pubmed.ncbi.nlm.nih.gov/42245865/). Large, prospective randomized trials are urgently needed to clarify these risks (https://pubmed.ncbi.nlm.nih.gov/42245865/). Regarding the adequacy of warnings, the prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions and the risk of pulmonary aspiration during surgery, but it does not explicitly mention gastroparesis as a potential adverse effect. This may leave patients and healthcare providers unaware of the specific risk of developing gastroparesis, which can be a chronic and debilitating condition. The label notes that gastrointestinal adverse reactions occur more frequently with Ozempic than placebo and that some patients discontinue treatment due to these reactions, but it does not provide specific guidance on monitoring for gastroparesis symptoms or managing the condition if it develops.

Legal Considerations for Georgia Patients

For patients in Georgia who have developed gastroparesis after using Ozempic, attorney-related considerations are important. The statute of limitations for personal injury claims in Georgia is generally two years from the date of injury or from when the injury was discovered or should have been discovered. This means that affected patients must file a lawsuit within this timeframe to preserve their legal rights. The timeline between exposure to Ozempic and documented harm is critical. Gastroparesis symptoms may develop gradually, and the link to Ozempic may not be immediately apparent. Patients should document the start date of Ozempic use, the onset of gastrointestinal symptoms, and any medical diagnoses of gastroparesis. This documentation can help establish the causal connection and support a legal claim. In summary, Ozempic is associated with a higher incidence of gastrointestinal adverse reactions, including nausea, vomiting, and abdominal pain, which can be indicative of gastroparesis. The drug's mechanism of delaying gastric emptying can lead to retained gastric contents and, in rare cases, pulmonary aspiration. The prescribing information does not explicitly warn about gastroparesis, which may affect the adequacy of warnings. Patients in Georgia who develop gastroparesis after using Ozempic should be aware of the two-year statute of limitations and seek legal advice promptly to protect their rights.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic-related gastroparesis claims in Georgia?

In Georgia, the statute of limitations for personal injury claims, including those related to Ozempic-induced gastroparesis, is generally two years from the date of injury or from when the injury was discovered or should have been discovered. It is crucial to consult with an attorney promptly to ensure your claim is filed within this timeframe.

Does Ozempic's prescribing information warn about gastroparesis?

The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions and the risk of pulmonary aspiration during surgery, but it does not explicitly mention gastroparesis as a potential adverse effect. This lack of specific warning may be relevant in legal claims regarding the adequacy of warnings.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.